Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
Filter Awards
| Disease | Cell Type | Therapeutic or Technology |
Institution |
Stage | Project Objective | Details |
|---|---|---|---|---|---|---|
| Blood Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | Angiocrine |
 |
Clinical Trial, Phase 1 or Phase 1/2 | |
| Blood Cancer | Adult Stem Cell | Donor cell therapy | Angiocrine |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Parkinson's Disease | iPS Cell | Cell processing & handling | Aspen Neuroscience | Research Insights, Tool/Resources/Bottleneck | ||
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Boston Children's Hospital |
 |
Clinical Trial, Phase 2 | |
| Parkinson's Disease | Vital Research Opportunity | Gene Therapy, cell free | Brain Neurotherapy Bio |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Amyotrophic Lateral Sclerosis | Adult Stem Cell | Personalized cell therapy | BrainStorm |
 |
Clinical Trial, Phase 3 | |
| Retinitis Pigmentosa | Adult Stem Cell | Donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Pulmonary Hypertension, Vascular Disease |
Adult Stem Cell | Donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Amyotrophic Lateral Sclerosis | Adult Stem Cell | Gene-modified, donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Donor cell therapy | Celularity Inc |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Intestinal Disease, Neurological Disorders |
iPS Cell | Donor cell therapy | CHLA |
 |
Pre-IND/IDE or Equivalent | |
|
Blood Cancer, Bone Marrow Transplant and Viral Infection |
Adult Stem Cell | Donor cell therapy | CHLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Liver Disease | iPS Cell | Gene-modified, donor cell therapy | CHLA |
 |
Development Candidate, Proof of Concept | |
|
Beta Thalassemia, Sickle Cell Disease |
Adult Stem Cell | Diagnostic Test | CHORI |
|
Regulated Lab Test, Ready for Validation | |
|
Brain Cancer, Breast Cancer |
Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS | Personalized cell therapy | COH |
 |
IND | ||
|
COVID-19, Respiratory Disorders |
Vital Research Opportunity | Convalescent Plasma | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| COVID-19 |
Embryonic Stem Cell, iPS Cell |
Gene-modified, donor cell therapy | COH |
|
Proof of Concept | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Canavan Disease | iPS Cell | Gene-modified, personalized cell therapy | COH |
|
Pre-IND/IDE or Equivalent | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
IND | |
| Ovarian Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Development Candidate, Proof of Concept | |
| Hemophilia A | Adult Stem Cell | Gene modification | COH |
|
Development Candidate, Proof of Concept | |
| Ovarian Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
|
Development Candidate, Proof of Concept | |
| Sickle Cell Disease | Adult Stem Cell | Donor cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Donor cell therapy | ExCellThera Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Dementia | iPS Cell | Donor cell therapy | Gladstone |
|
Development Candidate, Proof of Concept | |
| Severe Combined Immunodeficiency, X-linked (X-SCID) | Adult Stem Cell | Antibody | Jasper Therapeutics, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Retinitis Pigmentosa | Therapeutic Approach | jCyte |
|
Clinical Trial, Phase 2 | ||
| Retinitis Pigmentosa | Other | Donor cell therapy | jCyte |
|
Clinical Trial, Phase 2 | |
| Spinal Cord Injury | Embryonic Stem Cell | Donor cell therapy | Lineage Cell |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Type 1 diabetes | Embryonic Stem Cell | Gene-modified, donor cell therapy | Lundquist Institute |
|
Development Candidate, Proof of Concept | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Medeor Therapeutics |
|
Clinical Trial, Phase 3 | |
| Epilepsy | Embryonic Stem Cell | Donor cell therapy | Neurona Therapeutics |
|
Research Insights | |
| Epilepsy | Embryonic Stem Cell | Donor cell therapy | Neurona Therapeutics |
|
Pre-IND/IDE or Equivalent | |
|
Immune Disease, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | Orchard Therapeutics |
|
Clinical Trial, Phase 2 | |
| Multiple Myeloma | Adult Stem Cell | Gene-modified, personalized cell therapy | Poseida Therapeutics |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Bone or Cartilage Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Leukocyte Adhesion Deficiency |
Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
COVID-19, Respiratory Disorders |
iPS Cell | Small molecule therapy | Sanford-Burnham |
|
Development Candidate, Proof of Concept | |
| Brain Injury, hypoxic, ischemic | Adult Stem Cell | Donor cell therapy | Sanford-Burnham |
|
Pre-IND/IDE or Equivalent | |
| Beta Thalassemia | Adult Stem Cell | Gene-modified, personalized cell therapy | Sangamo |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Autism | iPS Cell | Small molecule therapy | Scripps |
|
Development Candidate, Proof of Concept | |
| COVID-19 | iPS Cell | Small molecule therapy | Scripps |
|
Development Candidate, Proof of Concept | |
|
Immune Disease, Severe Combined Immunodeficiency, X-linked (X-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | St. Jude |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Embryonic Stem Cell | Cell processing & handling | Stanford |
|
Research Insights | ||
| Hearing Loss | Adult Stem Cell | Protein/peptide therapy | Stanford |
|
Development Candidate, Proof of Concept | |
|
Bladder or Urinary Tract Disorder, Incontinence |
iPS Cell | Personalized cell therapy | Stanford |
|
Pre-IND/IDE or Equivalent |
Pages
